SS-31 peptide claims on TikTok: what the science says

What did @thepinkboxmissb actually say?

The creator shared what she called a "master cheat sheet" for SS-31, a mitochondria-targeting peptide. She recommended "1-3 milligram daily or every other day" for general mitochondrial support, up to "5 milligram daily for short cycles" for higher or short-term support, and a cycling protocol of "eight weeks on, three weeks off." She also noted SS-31 should be taken in a fasted state and that doses should be "titrated slowly away" when finishing a cycle.

This is a specific, structured dosing protocol delivered to over 11,000 viewers. The disclaimer "not medical advice, only for research and education purposes" does not change what the content actually is: a dosing recommendation for a research compound with no FDA approval for human use.

Does the science back this up?

Partially, but with major caveats. The human data on SS-31 is thin, and none of the published clinical trials use the dosing ranges she describes. Most of what exists comes from animal studies or small human trials using intravenous or subcutaneous administration under clinical supervision.

SS-31 (also known as Elamipretide or MTP-131) has been studied in humans primarily for heart failure and mitochondrial myopathy. The MMPOWER-3 trial (Karaa et al., 2018, JAMA Neurology) used 40 mg/day subcutaneous injections in patients with primary mitochondrial myopathy and found no statistically significant improvement on its primary endpoint. Earlier phase II trials (Gibson et al., 2016, JACC Heart Failure) showed some hemodynamic improvements in heart failure patients, but again using IV administration in clinical settings. The 1-5 mg daily range she cites does not appear in peer-reviewed human trials. It likely originates from peptide community forums or compounding pharmacy protocols, not published research.

What did they get wrong (or right)?

She gets partial credit for the fasted-state recommendation. There is a reasonable pharmacokinetic argument for subcutaneous peptide absorption being more consistent in a fasted state, though this is not specifically studied for SS-31 in published literature.

The 8-weeks-on, 3-weeks-off cycling guide is not supported by published human data. No clinical trial for SS-31 has used this cycling structure. It appears to be borrowed from general peptide cycling conventions applied to other compounds. That is a meaningful problem: SS-31 has a different mechanism than growth hormone secretagogues or repair peptides like BPC-157, so transplanting generic cycling logic onto it is not evidence-based.

The dose range itself is the biggest issue. Presenting "1-3 mg" and "up to 5 mg" as tiered guidance implies a safety and efficacy profile that has not been established in humans at these doses. The MMPOWER-3 trial used doses eight times higher under medical supervision and still did not meet its primary endpoint. Lower doses in unsupervised settings have unknown effects. Framing this as a "cheat sheet" is misleading regardless of the disclaimer.

What should you actually know?

SS-31 is a genuinely interesting compound in mitochondrial research, and the science of mitochondrial-targeted antioxidants is a real and active field. That does not mean this cheat sheet is safe to follow. Here is what the actual evidence supports.

• SS-31 works by binding to cardiolipin, a phospholipid in the inner mitochondrial membrane, reducing oxidative stress at the source. This mechanism is well-established in animal models (Szeto, 2014, Phytochemistry Reviews).
• Human clinical results have been disappointing at scale. The largest trial failed its primary endpoint (Karaa et al., 2018).
• No published human trial has validated the 1-5 mg subcutaneous daily dosing range described in this video.
• SS-31 is not FDA-approved. It is available only as a research compound or through compounding pharmacies, which are not equivalent to pharmaceutical-grade clinical formulations.
• The cycling protocol has no clinical evidence base for this specific peptide.